CoChat

The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis

Open access
Zhou, Jingjing, Wang, Fang, Li, Sen · 2025 · Frontiers in Endocrinology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Objective: This study assesses the efficacy and safety of the novel oral small molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) danuglipron and orforglipron in the treatment of type 2 diabetes (T2DM) and obesity through systematic review and meta-analysis. Methods: Electronic databases (PubMed, Web of Science, Cochrane Library and Embase) were systematically searched up to 20 May 2025 to include randomised controlled trials evaluating danuglipron/orforglipron in patients with T2DM and/or obesity. Changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI), weight and body mass index (BMI) compared with baseline post-treatment were evaluated using random-/fixed-effects models, alongside safety outcomes. Results: Eight studies with low bias risk involving 1,454 participants were analysed. Meta-analysis results demonstrated that danuglipron significantly decreased HbA1c (mean difference [MD]: −0.90; 95% CI: −1.06, −0.74), FPG (MD: −24.66; 95% CI: −30.45, −18.86) and weight (MD: −2.17; 95% CI: −3.10, −1.23) and improved FPI (MD: 2.94; 95% CI: 1.50, 4.38). Orforglipron also showed significant positive effects on HbA1c (MD: −1.02; 95% CI: −1.18, −0.86), FPG (MD: −26.91; 95% CI: −31.05, −22.78), weight (MD: −6.28; 95% CI: −8.45, −4.11) and BMI (MD: −2.64; 95% CI: −3.38, −1.89). However, both danuglipron and orforglipron were associated with the occurrence of treatment-related adverse events and gastrointestinal adverse events (AEs). Conclusion: The oral GLP-1 RAs danuglipron and orforglipron are capable of improving blood glucose levels and reducing weight; however, they also pose an increased risk of gastrointestinal AEs. Further longitudinal studies are warranted to gain a deeper understanding of their efficacy, safety and tolerability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2025.1646956

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of study selection.
Figure 1 Flowchart of study selection.CC BY · PubMed Central
Figure 2 Forest plot of change of HbA1c (%) from baseline following danuglipron and orforglipron.
Figure 2 Forest plot of change of HbA1c (%) from baseline following danuglipron and orforglipron.CC BY · PubMed Central
Figure 3 Forest plot of change of FPG (mg/dl) from baseline following danuglipron and orforglipron.
Figure 3 Forest plot of change of FPG (mg/dl) from baseline following danuglipron and orforglipron.CC BY · PubMed Central
Figure 4 Forest plot of change of FPI (μIU/mL) from baseline following danuglipron and orforglipron.
Figure 4 Forest plot of change of FPI (μIU/mL) from baseline following danuglipron and orforglipron.CC BY · PubMed Central
Figure 5 Forest plot of change of body weight from baseline following danuglipron and orforglipron.
Figure 5 Forest plot of change of body weight from baseline following danuglipron and orforglipron.CC BY · PubMed Central
Figure 6 Forest plot of change of BMI from baseline following orforglipron.
Figure 6 Forest plot of change of BMI from baseline following orforglipron.CC BY · PubMed Central
Figure 7 Forest plot of any TEAE incidence risk following danuglipron and orforglipron.
Figure 7 Forest plot of any TEAE incidence risk following danuglipron and orforglipron.CC BY · PubMed Central
Figure 8 Forest plot of GI AE incidence risk following danuglipron and orforglipron.
Figure 8 Forest plot of GI AE incidence risk following danuglipron and orforglipron.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 3

Metadata

Authors
Zhou, J., Wang, F., & Li, S.
Affiliations
  • Shanxi University of Medicine (CN)
  • Shanxi Fenyang Hospital (CN)
Corresponding author
Zhou, Jingjing
Venue
Frontiers in Endocrinology
Published
2025-12-10
Volume
16
Pages
1646956-1646956
ISSN
1664-2392 (ISSN-L)
OpenAlex
W7113901679
Cited by
3
References
33
Citations by year
2026: 3
FWCI
0.41
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Shanxi Medical University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
orforglipron, GLP-1 receptor agonists, type 2 diabetes, obesity, HbA1c, fasting blood glucose, insulin, weight loss, body mass index, gastrointestinal adverse effects, drug safety, antidiabetic efficacy, GLP-1 receptor antagonists
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Benzimidazoles, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Obesity, Oxadiazoles, Piperidines, Randomized Controlled Trials as Topic, Treatment Outcome, Fluorine Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2025.1646956
The paper
Zhou, J., Wang, F., & Li, S. (2025). The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1646956

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.